Dr. Reddy's Laboratories Ltd
RDY
Positions held
Your positionsRDY isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Dr. Reddy's Laboratories operates in a competitive healthcare sector with a strong focus on specialty and generic drugs, positioning itself well for growth as global healthcare demands increase.
- In the latest quarter, revenue increased by 7% compared to the prior quarter, reaching $80.7 billion.
- The operating margin expanded to 3.8%, indicating improved operational efficiency.
- The company faces challenges with a declining revenue growth rate of -5.6%, which may impact future profitability.
- Earnings growth has decreased significantly, showing a decline of -68.7% year-over-year.
- The gross margin fell to 46.5% from 57.3% in the previous quarter, reflecting potential pricing pressures or increased costs.
Fundamentals
| Market cap | $10.16B | Enterprise value | $54.68B | Trailing P/E | 27.73 | Forward P/E | 19.02 |
| PEG | 1.64 | Price / book | 15.29 | Beta | 0.25 | Dividend yield | 0.68% |
| Revenue growth | -5.6% | Earnings growth | -68.7% | Gross margin | 50.2% | Operating margin | 4.3% |
| Profit margin | 10.0% | ROE | 8.8% | ROA | 4.0% | Debt / equity | 0.19 |
| Current ratio | 1.90 | Free cash flow | -$3.91B | Analyst recommendation | hold | Mean target | $13.23 |
| 52w high | $15.67 | 52w low | $11.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $80.7B | $75.2B | $87.3B | $88.1B | $85.5B | — |
| Op margin | 3.8% | 1.1% | 16.4% | 20.3% | 19.7% | — |
| Net income | $4.4B | $2.2B | $12.1B | $14.4B | $14.2B | — |
| Gross margin | 46.5% | 57.3% | 53.6% | 54.7% | 56.9% | — |
| Gross profit | $37.5B | $43.0B | $46.8B | $48.1B | $48.6B | — |
| Operating income | $3.0B | $829M | $14.3B | $17.9B | $16.8B | — |
- Revenue +7% vs prior quarter ($80.7B vs $75.2B).
- Gross margin 46.5% (was 57.3% prior quarter).
- Operating margin expanded to 3.8%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $335.9B | $325.5B | $279.2B | $245.9B | — |
| Op margin | 14.9% | 22.1% | 23.4% | 24.0% | — |
| Net income | $42.9B | $56.5B | $55.7B | $45.1B | — |
| Gross margin | 52.8% | 58.5% | 58.6% | 56.7% | — |
| Gross profit | $177.3B | $190.4B | $163.6B | $139.3B | — |
| Operating income | $50.1B | $72.0B | $65.3B | $59.1B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-25 · NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
2026-07-28 · Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...
2026-07-23 · Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
2026-07-22 · Dr. Reddy's Laboratories Q1 Earnings Call Highlights
2026-07-12 · Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
Price (daily)
Full chart · RSI · MACD · patterns